Introduction
Birt-Hogg-Dube´(BHD) syndrome is a rare inherited cancer susceptibility disease characterized by benign hair follicle tumors and lung cysts in a majority of patients, and renal cell carcinoma (RCC) in approximately one third of diagnosed BHD cases . Genetic analyses of families affected by BHD syndrome previously identified germline mutations in the BHD gene on chromosome 17p11.2, most of which were predicted to prematurely truncate the encoded protein (Nickerson et al., 2002; Toro et al., 2008) . Mutational analyses of BHD-related tumors from patients, as well as those from mouse and rat models of BHD syndrome, identified inactivating 'second hits' in the remaining wild-type BHD allele, formally establishing BHD as a tumor suppressor (Okimoto et al., 2004; Vocke et al., 2005; Hasumi et al., 2009) . BHD inactivation has also been described in a subset of von Hippel-Lindau-independent RCC syndromes, in approximately one third of sporadic renal cancers, and in 60% of idiopathic cystic lung disease cases (Khoo et al., 2003; Gunji et al., 2007; Woodward et al., 2008) .
While the genetic basis of BHD syndrome is well understood, the cellular and molecular mechanisms involving the protein encoded by BHD, also called Folliculin, remain unclear. Dissecting BHD's molecular functions is particularly challenging since the BHD gene product bears no sequence or functional homology to any known protein. Studies in Schizosaccharomyces pombe have suggested a role for the putative yeast BHD ortholog in amino-acid homeostasis, while siR-NA-mediated knockdown of Drosophila BHD in the fly has implicated it in male germline stem cell maintenance through Stat and/or BMP signaling (Singh et al., 2006; van Slegtenhorst et al., 2007) . Finally, mammalian cell culture analyses and mouse models have linked BHD and mammalian target of rapamycin (mTOR) signaling, potentially mediated through an interaction with its binding partner, called Folliculininteracting protein, and AMP-activated kinase (Baba et al., 2006) . These studies demonstrate that BHD loss can paradoxically result in either stimulation or inhibition of mTOR depending on the system examined (Baba et al., 2006 (Baba et al., , 2009 Hudon et al., 2008 Hudon et al., , 2010 .
To investigate the cellular and molecular mechanisms by which BHD suppresses tumorigenesis, we established Bhd À/À embryonic stem (ES) cell lines, since the early lethality of Bhd À/À embryos precluded the development of other cellular models. We observed that the major cellular consequence of BHD loss is resistance to apoptosis caused by decreased Bim expression. This phenomenon was independent of mTOR and ERK hyperactivation and was instead associated with a general loss of TGFb-dependent chromatin modifications and transcription. These data present new insight into how BHD functions as a tumor suppressor and suggest novel targeted therapeutics for BHD syndrome, sporadic RCC, and cystic lung disease.
Results
Homozygous mutant Bhd embryos die during early embryogenesis To define the basic molecular functions of BHD, we initially attempted to establish mouse embryonic fibroblasts from a gene-trap mouse model. In order to fully characterize this mutant Bhd allele (denoted as m), we mapped the insertional position of the trap cassette to intron 8 of the murine Bhd gene, and established Southern and PCR-based genotyping assays to discriminate wild type from the m allele (Figures 1a-c). Using multiple quantitative real-time (qRT)-PCR probes, we observed a 40-50% reduction in Bhd mRNA expression in Bhd þ /m ES cells compared with Bhd þ / þ controls by qRT-PCR ( Figure 1d ), and confirmed expression of the BHD-bgeo fusion product by staining the ES cells with X-Gal (Figure 1e ).
Bhd þ /m intercrosses yielded no viable Bhd m/m embryos after e7.5; although we were unable to genotype e6.5 embryos, we observed that B25% of these were severely abnormal or partially resorbed upon dissection, exhibiting grossly atrophied and disorganized egg cylinders, distorted visceral endoderm and lack of cavitation (Figures 1f and g) . This phenotype is consistent with a recently reported embryonic lethal phenotype for an independent mutant Bhd allele (Hasumi et al., 2009) . Loss of BHD does not affect proliferation, but results in decreased cellular size and resistance to cell-intrinsic apoptosis Since the early lethality of the Bhd m/m embryos precluded the development of differentiated cell types, we generated an ES cell model for in vitro studies. To do this, we used an independent mutant Bhd allele (denoted as '-') with a gene trap in Bhd intron 1, which ablated expression of the entire Bhd open reading frame. The Bhd þ /À ES cells were characterized in the same manner as the Bhd þ /m cells to validate efficacy of the trap cassette ( Supplementary  Figures 1a-e ).
Bhd À/À ES cells were generated from the parental Bhd þ /À cells as shown by PCR, and western blot confirmed complete loss of BHD protein expression (Figures 2a and b) . To verify BHD loss did not affect the undifferentiated state of Bhd À/À ES cells, we analyzed protein levels of Oct-4, Nanog, Sox2 and phospho-Stat3, and alkaline phosphatase activity in Bhd þ / þ , Bhd þ /À , and Bhd À/À cells ( Supplementary Figures 2a-c) . We observed no difference in all parameters of ES cell pluripotency, allowing for valid comparison in in vitro studies across genotypes.
To gain insight into BHD's tumor suppressive properties, we assessed Bhd þ / þ , Bhd þ /À , and Bhd À/À ES cell lines for proliferation, cell growth, and apoptotic responses. Bhd À/À ES cells did not proliferate significantly faster at days 1-3 after plating, but confluent cultures analyzed at day 4 were found to contain 15-20% more cells compared with Bhd þ / þ and Bhd þ /À counterparts ( Figure 2c ). Intriguingly, this difference was attributed to a 15-20% decrease in cellular volume in Bhd À/À cells ( Figure 2d ).
Finally, we evaluated the response of Bhd À/À cells to cell-intrinsic apoptosis by starving cells of serum, glucose, or amino acids for 24 h. Bhd À/À cells clearly demonstrated a resistance to all three apoptosis-inducing stresses as revealed by light microscopy, decreased accumulation of sub-G1 populations, and reduced Caspase-3 and Parp cleavage . This effect was specific to the intrinsic apoptotic pathway, as Bhd À/À cells showed no differential response to the death-receptor ligand Tumor necrosis factor a ( Figure 2g ). Thus, BHD deficiency does not confer an obvious increase in cellular proliferation or growth, but does reduce cell-intrinsic apoptosis, thereby identifying a plausible cellular role for BHD as a tumor suppressor.
Bim expression is lost in Bhd À/À cells and BHD-related tumors and contributes to apoptotic resistance The cell-intrinsic apoptotic resistance of Bhd À/À cells could either be due to increased intracellular nutrient stores, an effect previously observed in a mutant yeast model of BHD, or result from a defect in the cell-intrinsic death machinery (van Slegtenhorst et al., 2007) . To assess the former possibility, we measured levels of 13 different intracellular amino acids by high performance liquid chromatography and observed no differences between Bhd þ / þ and Bhd À/À ES cells, suggesting that nutrient homeostasis was not playing a role in the apoptoticresistance phenotype (Figure 3a ).
To determine if the cell-intrinsic death machinery might be impaired in Bhd À/À ES cells, we examined protein levels of several Bcl2 family members and found many pro-apoptotic BH3-only proteins to be misregulated in Bhd À/À cells. Both extra-long (EL) and long (L) isoforms of Bim, as well as Pumaa and Bad were significantly downregulated in Bhd À/À ES cells, while Bid and BMF levels were upregulated ( Figure 2b ). Bik, Noxa, and Pumab, as well as the multi-domain Bcl2 family members BclXL and Bak were unchanged. Similar results were obtained using three independent BHD-deficient ES clones homozygous for the Bhd m allele ( Supplementary Figures 3a and b ). We focused primarily on Bim regulation in subsequent experiments, given its dominant role among BH3-only proteins in mediating the cell-intrinsic death response and frequent loss in RCC (Kim et al., 2006; Zantl et al., 2007; Guo et al., 2009) .
To test whether the apoptotic resistance of Bhd À/À cells was Bim dependent, we restored either BimEL or Bhd expression by retroviral transduction in Bhd À/À cells. Restoration of BimEL or Bhd expression, or treatment of cells with the BH3-only chemical mimetic ABT-737, rescued the apoptotic response of Bhd À/À ES cells to amino-acid deprivation, as assessed by FACs analysis (Figure 3c , upper panel), and Parp and Caspase-3 cleavage (Figure 3c , lower panel). Importantly, Bhd reconstitution was sufficient to restore Bim protein levels. Interestingly, autophagy inhibitors 3-methyladenine and chloroquine rescued the apoptotic response in Bhd À/À cells (Figure 3c ), similar to apoptosis-deficient Bax À/À /Bak À/À double knockout cells (Lum et al., 2005) .
To determine whether loss of BHD results in Bim deficiency in vivo, we performed immunohistochemistry on BHD-related tumors from both human BHD patients and aged Bhd þ /m mice. 3/3 human-derived tumors (one fibrofolliculoma, one chromophobe-clear cell hybrid RCC, and one chromophobe RCC) and 5/5 solid murine renal tumors (four hybrid oncocytic and one papillary mass projecting from a cyst), exhibited absent or significantly reduced Bim expression, confirming that loss of Bim expression is a common event in BHD-related tumors of diverse histologies (Figure 3d ).
Bim is transcriptionally downregulated in Bhd À/À cells independent of mTORC1, mTORC2, ERK, or GCN2-eIF2a pathway aberrations Bim is regulated transcriptionally by several wellcharacterized signal transduction pathways, translationally by miRNAs, and on the level of protein stability (Dijkers et al., 2000; Dehan et al., 2009; Su et al., 2009) . We initially assessed Bim mRNA and found it to be decreased by B80% in Bhd À/À cells compared with Bhd þ / þ and Bhd þ /À cells (Figure 4a ). To investigate a possible additional role for enhanced proteolytic degradation of Bim, we treated Bhd À/À cells with the proteasome inhibitor MG-132, but observed no increase in Bim protein ( Supplementary Figure 4a) (Dehan et al., 2009 ). We also examined levels of mir-19 and mir-92, miRNAs previously shown to regulate Bim translation in ES cells (Su et al., 2009 ), but detected no differences between Bhd À/À and control cells ( Supplementary  Figure 4b ).
To determine which transcriptional networks and upstream signaling pathways were involved in Bim misregulation, we investigated the mTOR and ERK pathways that have previously been linked to Bim regulation (Dijkers et al., 2000; Dehan et al., 2009) , and are hyperactivated in late-stage cysts and tumors derived from a mutant Bhd mouse model (Baba et al., 2008) . Western blot analysis of Bhd þ / þ , Bhd þ /À , and Bhd À/À ES cells revealed that Bhd À/À ES cells exhibited hyperphosphorylation of S6K1 and 4E-BP1 (indicative of increased mTOR complex 1 (mTORC1) activity), hyperphosphorylation of Akt and the FoxO family of Figure 2 Bhd À/À ES cells do not have a proliferative or growth advantage, but are resistant to apoptosis. (a) PCR genotypes verifying loss of wild-type Bhd allele in three independent ES clones, designated as '1', '2', and '3,' after step-up selection. WT=wild-type, Mut=mutant alleles. (b) Western blot demonstrating loss of BHD protein expression in three independent Bhd À/À ES clones with a non-specific (NS) band shown as a loading control. (c) Growth curve showing Bhd À/À ES cells proliferate at similar rates to Bhd þ / þ and Bhd þ /À counterparts, but have increased saturation density at day 4. (d) Coulter counter size measurements showing Bhd À/À cells are significantly smaller than Bhd þ / þ and Bhd þ /À ES cells (*P ¼ 0.000623). Bhd À/À ES cells are resistant to stress-induced apoptosis as shown by (e) brightfield images of Bhd þ / þ and Bhd À/À ES cells starved of amino acids for 1 day, or (g) FACs analysis of cells containing sub-G 1 DNA content after 1 day serum, glucose and amino-acid (AA) deprivation compared with Bhd þ / þ and Bhd þ /À cells (*Po0.0000345), but not by Tumor necrosis factor a treatment. proteins (indicative of mTOR complex 2 (mTORC2) hyperactivation) and hyperactivation of the MEK-ERK-p90RSK cascade (Figure 4b ).
To determine if these pathways were playing a role in decreased Bim levels in Bhd À/À cells, we treated cells with inhibitors of each at doses that reduced signaling in Bhd À/À cells to levels observed in Bhd þ / þ cells. We found that pharmacologic inhibition of PI3K-dependent mTORC2, MEK, or mTORC1 activities, either singly or in combination, was insufficient to restore Bim protein levels in Bhd À/À cells (Figure 4c ). Treatment of Bhd À/À cells with the same panel of inhibitors was similarly unable to rescue the death-resistance phenotype as assessed by sub-G1 population quantification (Figure 4d , upper panel), or Caspase and Parp cleavage following 2-day amino-acid starvation (Figure 4d , lower panel).
Bim expression is also known to be regulated by Chop, a transcription factor activated downstream of eukaryotic initation factor a (eIF2a) kinases as part of the unfolded protein response and as an adaptation to nutrient withdrawal (Puthalakath et al., 2007) . Interestingly, Bhd À/À cells exhibited decreased basal and aminoacid deprivation-induced levels of p-eIF2a levels, but not ER stress-induced p-eIF2a after thapsigargin treatment ( Supplementary Figures 5a-c) . However, induction of the downstream effectors ATF4 and Chop was only slightly attenuated in response to amino-acid deprivation ( Supplementary Figure 5b) . More importantly, reintroduction of Chop into Bhd À/À cells failed to rescue Bim expression ( Supplementary Figure 5d ). Collectively, these data suggest that the downregulation of Bim and apoptotic resistance observed in Bhd À/À cells are not due to signaling aberrations in the mTORC1, mTORC2, ERK, and eIF2a signaling pathways.
Bhd À/À ES cells exhibit many phenotypic and molecular defects characteristic of TGFb-pathway mutants We next considered the TGFb pathway, since many reports had previously shown it regulated Bim transcription in diverse cell types (Wildey et al., 2003; Ramjaun et al., 2007; Ramesh et al., 2008; Yu et al., 2008; Houde et al., 2009) . We first verified that the TGFb ligand family regulates Bim mRNA in ES cells by treating them with Activin, a TGFb family ligand to which ES cells are responsive. Bim mRNA was increased within 2 h of Activin treatment in Bhd þ / þ ES cells, which did not occur in Bhd À/À cells (Figure 5a ). To ascertain whether this effect was specific to Bim, we analyzed the mRNA levels of several other BH3-only family members in response to Activin. Contrary to Bim, Bid, BMF, and Bad mRNAs were not induced by Activin in wild-type cells, and actually appeared elevated in Bhd À/À cells (Supplementary Figure 6a) . The latter finding was consistent with increased Bid and BMF protein levels in Bhd À/À cells, but appeared opposite to that of Bad protein levels (Figure 3b ). While Pumaa mRNA was induced by Activin, this was not BHD dependent as it occurred in both Bhd þ / þ and Bhd À/À cells ( Supplementary Figure 6a) . Taken together, these data identify Bim as a specific BH3-only mRNA regulated by TGFb in a BHD-dependent manner.
To determine if TGFb-mediated transcriptional defects were a general phenomenon in Bhd À/À cells, we Figure 5 Bhd À/À ES cells exhibit phenotypes and transcriptional defects characteristic of TGFb-signaling components. (a) Bhd þ / þ and Bhd À/À ES cells were cultured for 24 h in N2B27 media, then stimulated with 10 ng/ml of Activin. Bim mRNA levels were significantly induced in Bhd þ / þ cells after stimulation, but not in Bhd À/À ES cells (*P ¼ 0.00864). (b) qRT-PCR analysis showing canonical TGFb target genes PAI-1, p15, Lefty1, and Pitx2 are significantly downregulated in multiple Bhd À/À ES cell clones labeled 1, 2 and 3 (*Po0.04). (c) X-gal stained 70 Â image of (a) whole mount or 200 Â image of (b) sectioned yolk sac taken from a e10.5 Bhd þ /m embryo exhibiting high Bhd expression in visceral endoderm of the yolk sac. (d) 200 Â image of day 12 EBs showing Bhd þ / þ EBs form expanded cystic structures reminiscent of yolk sacs while Bhd À/À EBs fail to do so. (e) qRT-PCR analysis on RNA from EBs, showing two independent Bhd À/À EBs (clones 1 and 2) fail to express maximal levels of mature yolk sac markers a-feto-protein (Afp) and Trithioredoxin (Ttr). Averages represent maximal expression levels for each mRNA, which occurred between days 6 and 9 of EB development (*Po1.0 Â 10 À5 for both mRNAs). (f) Quantification of benzediene-positive EBs that express hemoglobin (Hb) at day 10 in methylcellulose cultures demonstrating Bhd À/À EBs fail to form erythroid lineages (*P ¼ 2.32 Â 10 À6 ). Data represent the average of three independent experiments with error bars showing standard deviation. (g) qRT-PCR analysis of Gata-1 and CD34 mRNA expression in day 10 EBs in methylcellulose cultures, which is significantly reduced in Bhd À/À EBs (Po4.49 Â 10 À6 ). examined the basal mRNA levels of several established TGFb-transcriptional targets involved in diverse biological processes. mRNA levels for the cell cycle regulator p15, pro-apoptotic plasminogen inhibitor activator type I (PAI-1) and Lefty1 and Pitx2, which have developmental roles were all lower in Bhd À/À cells compared with Bhd þ / þ cells (Figure 5b ). Other canonical TGFb mRNA targets such as SnoN, p21, Col1a2, and Lefty2 were similarly downregulated in Bhd À/À cells (Supplementary Figure 6b ). Other TGFb targets previously implicated in cell cycle regulation and apoptosis were unaffected in Bhd À/À cells, including Gadd45b and p57, while the death-associated protein kinase was actually upregulated (Supplementary Figure 6c) . Overall, these data support a positive role for BHD in TGFb-mediated transcription that governs biological processes implicated in cancer such as apoptosis, cell cycle, and differentiation.
TGFb ligands and receptors are required for normal yolk sac vasculogenesis and embryonic hematopoiesis in vivo, and in ES cell-derived cystic embryoid body (EB) cultures in vitro (Dickson et al., 1995; Oshima et al., 1996; Goumans et al., 1999; Larsson et al., 2001) . Interestingly, strong BHD expression was observed in yolk sac visceral endoderm, as revealed by X-Gal staining of E10.5 embryos heterozygous for the Bhd m allele (Figure 5c ). To investigate whether BHD is required for yolk sac development, we generated day 12 EBs from Bhd þ / þ and Bhd À/À ES cells. Bhd À/À ES cells failed to form expanded cystic EBs, which are reminiscent of mature yolk sacs in vivo (Figure 5d ), or induce mature yolk sac markers a-fetoprotein (Afp) and Trithioredoxin (Ttr) (Doetschman et al., 1985) ( Figure 5e ). To further evaluate the role of BHD in embryonic hematopoietic stem cell development, we generated Bhd þ / þ and Bhd À/À EBs in methylcellulose cultures, which promotes the differentiation of hematopoietic lineages. Bhd À/À EBs failed to form hemoglobinized colonies at day 10 in culture (Figure 5f ; Supplementary Figure 6b ) and exhibited severely reduced mRNA levels of the erythroid gene Gata-1 and CD34 (a marker of both hematopoietic and endothelial lineages) (Figure 5g ). Interestingly, we observed a delayed induction of the mesodermal marker Brachyury, a super-induction of Fgf-5 and attenuated maintenance of Hnf4 at later stages ( Supplementary  Figure 7) . However, these minor effects are unlikely to explain the dramatic hematopoietic and yolk sac defects of Bhd À/À EBs, as maximal induction of these target genes was still robust in Bhd À/À EBs, increasing by orders of magnitude.
Bhd À/À cells exhibit hypo-acetylation of TGFb target gene promoters, resulting in their death-resistance phenotype Because BHD deficiency resulted in molecular and phenotypic defects similar to TGFb receptor and ligand mutants, we next investigated whether the transcriptional defects occurred at the level of receptor-mediated phosphorylation and nuclear translocation of Smadtranscriptional regulators. Therefore, we examined nuclear levels of phosphorylated and total receptorregulated Smad2 and the common partner Smad4, which form a complex and translocate to the nucleus upon cellular engagement of TGFb ligands (Zhang et al., 1996) . Western blot analysis did not reveal any differences in basal or Activin-induced nuclear accumulation of phospho-Smad2, total Smad2, or total Smad4 in Bhd þ / þ versus Bhd À/À ES cells (Figures 6a and b) .
Since Smads have previously been shown to activate transcription via acetylation of Histone H3 at target promoters, we performed chromatin immunoprecipitations for acetylated Histone H3 at the well-characterized Lefty1 promoter (Ross et al., 2006) . Whereas Bhd þ / þ ES cells demonstrated a significant increase in acetyl-H3 levels at the Lefty1 promoter following Activin treatment, Bhd À/À cells exhibited no response (Figure 6c ). A similar effect was observed at the promoter of PAI-1, which has been implicated in the apoptotic response (Kortlever et al., 2006; Lademann and Romer, 2008) ( Supplementary Figure 8a) . This difference was not due to a global reduction of acetyl-H3 levels, which appeared unaffected based on western blot assays (Figure 6d ). To determine whether restoration of acetylated Histone levels rescues Bhd À/À cell defects, Bhd À/À cells were treated with the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA), which restored mRNA levels of multiple TGFb target genes (PAI-1, p15, and Bim), Bim protein levels and cell death ( Figures  6e and f) . TSA appeared to have variable effects on other misregulated BH3-only proteins in Bhd À/À cells under nutrient deprivation ( Supplementary Figure 8b) . First, nutrient deprivation itself changed protein levels of some BH3-only proteins in Bhd À/À cells, with BMF actually decreasing and Bad equilibrating to wild-type levels, in contrast to nutrient replete conditions (Figure 3a) . TSA appeared to have no effect on Pumaa and Bid levels abundance under nutrient limitation, while it slightly elevated Bad and BMF levels. It seems unlikely, however, that Bad and BMF induction can explain the effects of TSA, given the ability of Bim reexpression alone to completely reverse the phenotype of Bhd À/À cells. In summary, BHD loss appears to contribute to apoptotic resistance and TGFb-dependent transcriptional defects via aberrations in chromatin modifications at target gene promoters including Bim (Figure 7) .
Discussion
To date, the cellular and molecular mechanisms of tumor suppression by BHD have remained elusive. Uncovering BHD protein functions is particularly challenging, given the lack sequence homology to any known protein. In this study, we initially observed that the major cellular consequence of BHD loss is apoptotic resistance due to loss of Bim expression, a phenomenon that can be observed in BHD-related renal tumors. These findings prompted us to ask what signaling pathways and/or transcriptional networks were implicated in this phenotype. We initially examined the mTOR pathway, as multiple published reports have shown correlations between BHD loss and mTOR activity (Hartman et al., 2009; Hasumi et al., 2009; Hudon et al., 2010) . While we did observe aberrant mTOR signaling in Bhd À/À cells, this was surprisingly unrelated to the apoptotic defects.
We turned our attention to the TGFb pathway, given its known role in regulating Bim transcription and tumor suppression. For instance, in humans, Smad4 germline mutations are associated with juvenile polyposis syndrome, which predisposes individuals to gastrointestinal cancers, and TGFbRI, TGFbRII and activin receptor II are mutated or downregulated in a broad spectrum of sporadic cancers (Levy and Hill, 2006) . Epigenetic silencing of genes involved in TGFb signaling has also been specifically observed in RCCs (McRonald et al., 2009) . Genetic ablation of these signaling components in mice have confirmed the tumor suppressive function of this pathway in models of colon, mammary, and pancreatic cancer (Massague, 2008) . Our data demonstrate that BHD loss results in yolk sac and hematopoietic defects reminiscent of TGFb receptor and ligand mutants. These phenotypes correlate with global aberrations in TGFb-mediated transcription, which appear to occur downstream of nuclear accumulation of phosphorylated Smads. Our data indicate this defect is most likely due to HDAC-mediated effects on chromatin at Smad-dependent promoters, given the ability of TSA to reverse the biological and molecular defects of Bhd À/À cells (Figure 7) . Further work will be needed to elucidate the nature of these effects.
Previous studies have suggested a contradictory role for mTOR in BHD-related tumorigenesis, showing that BHD loss can result in either upregulation or downregulation of mTOR signaling. These studies have been largely correlative and have not demonstrated a causative relationship between the signaling aberrations and biological outcomes (Baba et al., 2006; Hartman et al., 2009; Hasumi et al., 2009; Hudon et al., 2010) . While we observed increased mTOR signaling in Bhd À/À ES cells, as reported for late-stage kidney tumors taken from a BHD mouse model, this phenomenon appeared unrelated to the observed apoptotic resistance. We speculate that effects of BHD loss on mTOR signaling likely result from compensation and/or crosstalk with more proximal defects in TGFb signaling.
Collectively, the data presented here establish a novel model whereby BHD exerts its major tumor suppressive effect through TGFb-mediated transcriptional output to regulate cell-intrinsic apoptosis. A recent publication has further supported this model, suggesting TGFbdependent transcriptional defects in a human BHDderived tumor cell line (Hong et al., 2010) . This study demonstrated that BHD deficiency results in decreased levels of TGFb pathway signaling components themselves including the ligands TGFb-2 and Inhibin b A and Smad3. This contrasts with our data that demonstrate an effect of BHD downstream of signaling, on canonical Smad target gene promoters. Further, the report by Hong et al. suggested that TGFb-2 stimulates cell growth and survival in the absence of BHD, while the TGFb ligand Activin does the opposite. The latter is surprising in light of our findings, given the failure of BHD null ES cells to mount any transcriptional response to Activin treatment. This discrepancy likely derives from differential cell type, dosage and/or length of treatment, which has been well documented for TGFb ligands (Massague, 2008) . In any case, these molecular defects likely extend to other tumor-promoting effects such as cell-type specific proliferative advantages, due to p15 loss, and stromal alterations in BHD-related tumors in vivo (Massague, 2008) . Although our in vitro study did not uncover a role for BHD in proliferation, this is likely due to the unusual cell cycle machinery of ES cells, which is refractory to cyclindependent kinase inhibitors (Savatier et al., 1996; Faast et al., 2004) . It is probable that BHD loss and consequent defective TGFb-mediated signaling in vivo results in a proliferative advantage. Collectively, these findings suggest several targeted therapeutics for the treatment of BHD-related tumors, as well as sporadic cases of cystic lung disease and RCC, including BH3only mimetics, autophagy inhibitors, and HDAC inhibitors, which are all currently in clinical use for the treatment of other types of cancer.
Materials and methods

Sub-G 1 quantification
Cells were fixed and stained as previously described, then fluorescence was measured by flow cytometry (Riccardi and Nicoletti, 2006) . At least 10 000 cells were counted for each experiment and data were analyzed using FlowJo software.
X-Gal staining of tissues and embryos X-gal staining was carried out as previously described for both cells and whole mount tissues fixed in 4% paraformaldehyde according to the Sanger Institute gene-trap protocol. X-gal stained yolk sac sections came from tissue snap-frozen in OCT.
Alkaline phosphatase staining
Cells were stained using the Alkaline Phosphatase Detection Kit from Millipore (Bellerica, MA, USA) according to the manufacturer's instructions.
RNA isolation and qRT
RNA was extracted using Qiagen (Valencia, CA, USA) RNeasy columns with DNAase treatment and cDNA was written off B1 mg of RNA per reaction using the ABI (Foster City, CA, USA) one-step RT-PCR Master Mix. qRT-PCR reactions were run in triplicate on an ABI 7900HT machine for each experiment, utilizing either SYBR green or Taqman primer probe sets as noted in Supplementary Materials. All target mRNA levels were normalized to b-actin or 18s expression levels. All qRT-PCR data reflect average mRNA levels from three independent RNA extractions and reverse transcription reactions with error bars showing standard error of the mean.
Protein extraction and western blotting
Whole-cell lysates were prepared using a buffer containing 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 1% Triton, and freshly added protease inhibitor cocktail tablets from Roche (Basel, Switzerland) and 2 mM orthovanadate. Nuclear extracts were prepared using the Active Motif Nuclear Extraction kit, with 500 mM NaCl added after nuclease digestion followed by sonication of nuclear extracts. Lysates were run on polyacrylamide gels, transferred to nitrocellulose, blotted using standard protocols, and visualized on film using HRP-conjugated secondary antibodies and ECL reagent.
Cell size measurements
Cell size was measured using a Z2 Coulter particle size analyzer. At least 10 000 cells were measured for each experiment.
Characterization of gene-trapped ES cells and mice
Bhd þ /m ES cells were obtained from Bay Genomics and Bhd þ /À ES cells were obtained from the German Gene Trap Consortium, with isogenic parental Bhd þ / þ lines being obtained from each respective source. Gene-trap insertions were mapped by first PCR amplifying the boundary of the fusion transcript using primers within the 3 0 end of the trap cassette and within the sequence tag, on cDNA generated from heterozygous ES cells. The precise genomic location of the cassette was mapped by direct PCR amplification of the respective intronic-trap cassette boundary using primers in the exon just upstream from the insertion and within the 5 0 end of the trap cassette. Southern blots were carried out on either PvuII or BamHI-digested DNA on Bhd þ /m or Bhd þ /À ES cell, respectively, with 5 0 end-directed probes being generated by PCR amplification from genomic DNA and subsequent TOPO cloning. Bhd þ /m mice were generated and intercrossed and embryo collection was performed as previously described (Covello et al., 2006; Hartman et al., 2009) 
Proliferation assay
In all, 5 Â 10 4 cells were plated in a gelatinized 12-well plate and counted using the Countess automatic counter from Invitrogen (Carlsbad, CA, USA) each day after plating.
Immunohistochemistry
Paraffin-embedded tissue was immunostained using a rabbit polyclonal anti-Bim antibody from Novus following antigen retrieval in sodium citrate solution and developed using diaminobenzidine.
Embryoid bodies
For suspension cultures, 8 Â 10 6 ES cells were plated in 10 cm bacterial dishes in DMEM containing 10% FBS and b-mercaptoethanol. Media was changed every other day, with EBs being split 1:2 on day 3. Methylcellulose cultures and benezidiene staining were performed as previously described (Cooper et al., 1974; Adelman et al., 1999) .
Northern blotting
Northern blots for miRNAs were done as previously described (Gruber et al., 2009) .
Chromatin immunoprecipitation
In all, 1 Â 10 6 ES cells were fixed for 10 min in 1% formaldehyde for 10 min at room temperature. Crosslinking was quenched with 125 mM glycine for 5 min, then cells were lysed and sonicated to shear DNA for 3 min with on/off pulses using a Fisher Sonic Dismembranator Model 500 at 20% power. Chromatin immunoprecipitation was carried using the Imgenex QuikChIP kit according to the manufacturer's instructions using a pan acetyl-H3 antibody from Millipore. Eluted protein/DNA complexes were purified by phenol/ chloroform extraction and ethanol precipitation.
Statistics
All P-values were generated using a two-tailed Student's t-test.
